Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â Form 6-KÂ Report of Foreign Private IssuerPursuant to Rule 13a-16 or 15d-16under the Securities Exchange Act of 1934Â For the month of: December 2024Â Commission file number: 001-36578Â ENLIVEX THERAPEUTICS LTD.(Translation of registrantâ€™s name into English)Â 14 Einstein Street, Nes Ziona, Israel 7403618(Address of principal executive offices)Â Indicate by check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F.Â Form 20-FÂ â˜’Â Â Â Â Â Â Â Â Form40-FÂ â˜Â Â Â Â On December 11, 2024, Enlivex Therapeutics Ltd., acompany organized under the laws of the State of Israel, issued a press release announcing that the Israeli Ministry of Health authorizedthe initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetraâ„¢for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis. A copy of such press release is furnishedas Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.Â Â Exhibit No. Â Â Â 99.1 Press Release issued by Enlivex Therapeutics Ltd. on December 11, 2024. Â Â Â SIGNATURESÂ Pursuant to the requirements of the Securities Exchange Act of 1934, theRegistrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â Â Enlivex Therapeutics Ltd. Â (Registrant) Â Â Â By: /s/ Oren Hershkovitz Â Name:Â Title: Oren HershkovitzChief Executive Officer Â Â Â Date: December 11, 2024 Â Â Â Â Â Â Exhibit 99.1Â Â Enlivex Receives Regulatory Authorization for the Initiation ofa Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisNess-Ziona, Israel, December 11,2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the â€œCompanyâ€), a clinical-stage macrophage reprogrammingimmunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated PhaseI trial to evaluate the safety, tolerability and initial efficacy of Allocetraâ„¢ for injection into the temporomandibular joint(TMJ) in patients suffering from TMJ osteoarthritis.The study will be conducted bythe Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery. Notably, ShebaMedical Center was recently ranked among the top 10 hospitals in the world by Newsweek.Dr. Oren Hershkovitz, CEO of Enlivex,commented, â€œTMJ osteoarthritis is a unique disease that can affect young, otherwise healthy individuals, causing substantial painand impairment in oral function. In many cases, existing therapies fail to provide long-term relief, forcing patients to undergo multiplesurgeries as their disease progresses. Allocetraâ„¢ is currently being evaluated for other types of osteoarthritis and mayprovide a meaningful therapeutic option to alleviate this condition.â€The Phase I trial aims to recruitsix patients who have shown insufficient response to conventional treatments for TMJ osteoarthritis. The primary safety endpoint willmeasure the frequency and severity of adverse events and serious adverse events, and efficacy endpoints will assess changes from baselinein TMJ pain, joint functionality, and other disease parameters for up to 12 months following administration of Allocetraâ„¢.ABOUT ALLOCETRAâ„¢Allocetraâ„¢ is being developedas a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers,sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantlyto the severity of the respective diseases. By restoring macrophage homeostasis, Allocetraâ„¢ has the potential to provide a novelimmunotherapeutic mechanism of action for life-threatening clinical indications that are defined as â€œunmet medical needs,â€as a stand-alone therapy or in combination with leading therapeutic agents.ABOUT TemporomandibularJoint (TMJ) OSTEOARTHRITISTemporomandibular Joint (TMJ) disordersare the second most common musculoskeletal condition affecting 5 to 12% of the population globally, with an annual health cost estimatedat $4 billion1.Â Osteoarthritis of the TMJ is the most common form of arthritis in the TMJ, causing pain and stiffnessin the jaw. It may become difficult to chew or yawn due to painful and stiff jaw muscles.Â TMJ osteoarthritis is a degenerative diseaseof the joint, which culminates in the progressive destruction of all soft and hard tissue components of the TMJ. In patients who presentin early adulthood with severe clinical symptoms and catastrophic radiographic changes, there are significant implications for management,including the potential need for early total joint replacement. There are currently no effective long-term treatments for this disease2.ABOUT ENLIVEXEnlivex is a clinical stage macrophagereprogramming immunotherapy company developing Allocetraâ„¢, a universal, off-the-shelf cell therapy designed to reprogram macrophagesinto their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancingand resolution of life-threatening conditions. For more information, visitÂ http://www.enlivex.com.Â Â 1Bianchi et al., Sci Rep 20202Delpachitra et al., British Journal of Oral and Maxillofacial Surgery 60 (2022)Â Â Safe Harbor Statement:Â This press release containsforward-looking statements, which may be identified by words such as â€œexpects,â€ â€œplans,â€ â€œprojects,â€â€œwill,â€ â€œmay,â€ â€œanticipates,â€ â€œbelieves,â€ â€œshould,â€ â€œwouldâ€,â€œcould,â€ â€œintends,â€ â€œestimates,â€ â€œsuggests,â€ â€œhas the potential toâ€ and otherwords of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinicalstudies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATMÂ programs. All suchforward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Â Investors are cautioned that forward-looking statements involve risks and uncertainties that may affectÂ Enlivexâ€™sÂ businessand prospects, including the risks thatÂ EnlivexÂ may not succeed in generating any revenues or developing any commercial products;that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that wouldsupport the approval or marketing of these products for the indications being studied or for other indications; that ongoing studiesmay not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially fromthose set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantlyfrom the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the resultsof more developed, later-stage trials. The development of any products using the ALLOCETRATMÂ product line could alsobe affected byÂ a number ofÂ other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirementsfor data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricingand the impact of patents and other proprietary rights held by competitors and other third parties.Â In addition to the risk factorsdescribed above, investors should consider the economic, competitive, governmental,Â technologicalÂ and other factors discussedinÂ Enlivexâ€™sÂ filings with the Securities and Exchange Commission, including in the Companyâ€™s most recent AnnualReport on Form 20-F filed with the Securities and Exchange Commission.Â The forward-looking statements contained in this press releasespeak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, exceptas required under applicable law.ENLIVEX CONTACTShachar Shlosberger, CFOEnlivex Therapeutics, Ltd.shachar@enlivexpharm.comINVESTOR RELATIONS

CONTACTDave Gentry, CEORedChip Companies Inc.1-407-644-4256ENLV@redchip.comÂ Â